Results 31 to 40 of about 155 (115)

Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression [PDF]

Journal of Comparative Effectiveness Research, 2021
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter ...
Urvi Desai, Noam Y Kirson, Andrea Guglielmo, Hoa H Le, Timothy Spittle, Joshua Tseng-Tham, May Shawi, John J Sheehan   +7 more
openaire   +2 more sources

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review

Therapeutic Advances in Drug Safety, 2020
This narrative review aims to provide an overview of the current literature on the pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of ketamine, for the treatment of treatment-resistant depression (TRD).
Mohammed S Salahudeen, Cameron M Wright, Gregory M Peterson   +2 more
doaj   +1 more source

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression [PDF]

Clinical Pharmacology & Therapeutics, 2020
This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression (TRD). The Benefit–Risk Action Team framework was utilized to assess the benefit–risk profile using data from three induction studies and one maintenance study.
Katz, Eva G., Hough, David, Doherty, Teodora, Lane, Rosanne, Singh, Jaskaran, Levitan, Bennett   +5 more
openaire   +2 more sources

Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel

Annals of General Psychiatry, 2023
Background Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants.
Giuseppe Maina, Marina Adami, Giuseppe Ascione, Emi Bondi, Domenico De Berardis, Dario Delmonte, Silvia Maffezzoli, Giovanni Martinotti, Alessandra Nivoli, Elena Ottavianelli, the Delphi Panel Collaboration Group, Andrea Fagiolini   +11 more
doaj   +1 more source

Managing dissociative symptoms following the use of esketamine nasal spray: a case report

International Clinical Psychopharmacology, 2020
Patients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation. Manifestations of dissociation, such as feelings of detachment from the environment, can cause considerable anxiety for patients.
Pereira, Sophia, Brennan, Emily, Patel, Anjali, Moran, Melissa, Wallier, Jenny, Liebowitz, Michael R.   +5 more
openaire   +3 more sources

Real-world effectiveness and safety of esketamine intranasal spray combined with treatment-as-usual in psychiatric inpatients

European Psychiatry
Introduction Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major ...
E. Kavakbasi, M. Yilmaz, Ö. Bulut, H. Berndt, B. T. Baune   +4 more
doaj   +1 more source

Rapid treatment center for depression in China: constructive reflections and transnational implications

Frontiers in Psychiatry
Enhancing the early diagnosis and standardized treatment of major depressive disorder (MDD), as advocated by the National Health Commission of China, is a key priority in the mental health initiatives of the nation.
Zhan-Ming Shi, Xing-Bing Huang, Xing-Bing Huang, Yan-Ling Zhou, Yan-Ling Zhou, Yu-Ping Ning, Yu-Ping Ning, Gabor S. Ungvari, Gabor S. Ungvari, Yu-Tao Xiang, Yu-Tao Xiang, Wei Zheng, Wei Zheng   +12 more
doaj   +1 more source

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Health and Quality of Life Outcomes, 2023
Background Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning.
Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather M. Rozjabek, Jaskaran Singh   +6 more
doaj   +1 more source

Acute Safety and Efficacy of Intranasal Esketamine Spray Plus an Oral Antidepressant in Patient With Treatment-Resistant Depression From a University Hospital in Korea

BJPsych Open
Aims: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray in Korea. This study is aimed to evaluate the acute safety and efficacy of intranasal esketamine in patients with TRD from ...
Sang-Yeol Lee, Kyung-Joon Min, Chan-Mo Yang   +2 more
doaj   +1 more source

A real-world pharmacovigilance study of esketamine nasal spray

Medicine
Mining and updating the post-marketing safety signals of esketamine nasal spray for better identification of adverse drug event (ADE) signals and medication monitoring during clinical use to ensure patient medication safety. Downloading data from the US Food and Drug Administration Adverse Event Reporting System from Q1 2019 to Q2 2023, the reporting ...
Yaqing Chen, Hangye Gu, Wenwei Li, Yong Chen   +3 more
openaire   +3 more sources